Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a newer category of anti-hyperglycemic drugs that confer both nephroprotection and cardioprotection in patients with CKD and congestive heart failure, and are approved for the treatment of type 2 diabetes mellitus and its sequelae [27,30,31,32,33,34]. The gene discussed is SLC5A2; the disease is diabetes mellitus.